Development and evaluation of Deferasirox loaded nanoparticles for the treatment of Breast cancer: evaluation in-vitro and cell line study
DOI:
https://doi.org/10.30827/ars.v63i3.22142Keywords:
Deferasirox, Breast cancer, Nanoparticle, Cell line studyAbstract
Introduction: The aim of the present study was to study the potential efficacy of antitumor activity of nanoparticles loaded with Deferasirox In the current research work, nanoparticle loaded with Deferasirox were developed and evaluated to study its efficacy using breast cancer cell line. Nanoparticles of Deferasirox were prepared by solvent evaporation method using EthocelTM as a polymer and Kolliphor® P 188 as a surfactant. 23 factorial design used with concentration of polymer, concentration of surfactant and rpm as independent variables and percentage of entrapment efficiency and percentage of drug release as dependent variables. All formulations were prepared and evaluated for particle size, spectral studies, thermal studies, drug entrapment efficiency and in-vitro drug dissolution studies. In-vitro cell viability study on breast cancer cell line (MCF-7) was performed by MTT assay Developed nanoparticles possess the particle size 428.3 nm and PDI 0.626. Optimized formulation showed 82.62±1.04 maximum drug release after 6 h in a controlled manner and entrapment efficiency 72.64±0.24. The FTIR spectral studies and DSC thermogram indicated that there was no interaction between the drug and polymers used. Thus, Deferasirox nanoparticle formulation showed the anti-tumoral activity against human breast cancer cell line (MCF7) as per outcome of cell line study Nanoparticles of Deferasirox were stable and could be promising drug delivery for cancerous cells.
Downloads
References
Jaison J, Ahmed B, Yen S, Alain D, Michael K D. Review on nanoparticles and nanostructured materials: History, Sources, Toxicity And Regulations. Beilstein J Nanotechnol. 2018; 9: 1050–1074. Doi:10.3762/bjnano.9.98.
Liyanage PY, Hettiarachchi SD, Zhou Y, Ouhtit A, Seven ES, Oztan CY, Celik E, Leblanc RM. Nanoparticle-mediated targeted drug delivery for breast cancer Treatment. Biochimica et Biophysica Acta (BBA)- Reviews on Cancer. 2019; 1871(2): 419-433. Doi:10.1016/j.bbcan.2019.04.006
Thombre NA, Gide PS. Floating-bioadhesive gastroretentive Caesalpinia pulcherrima-based beads of amoxicillin trihydrate for Helicobacter pylori eradication. Drug Delivery. 2016;23(2):405-419. Doi: 10.3109/10717544.2014.916766.
Srai S, Bomford A, McArdle HJ. Iron transport across cell membranes: molecular understanding of duodenal and placental iron uptake. Best Practice & Research Clinical Haematology. 2002;15(2):243-259. Doi:10.1016/s1521-6926(02)90003-4
Kontoghiorghes J, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfusion science.2000; 23 (3): 211-223. Doi:10.1016/S0955-3886(00)00089-8
Rahdar A, Hajinezhad MR, Sargazi S, Barani M, Bilal M, Kyzas GZ. Deferasirox-loaded pluronic nanomicelles: Synthesis, characterization, in vitro and in vivo studies. J Mol Liq. 2021;323:114605. Doi:10.1016/j.molliq.2020.114605.
Dora CP, Singh SK, Kumar S, Datusalia, AK, Aakash D. Development and characterization of nanoparticles of glibenclamide by solvent displacement method. Acta Pol Pharm. 2010; 67 (3): 283-90.
Bolton S, Bon C. Pharmaceutical statistics: practical and clinical applications. 5th edn. Factorial Designs, Informa Healthcare, London, New York; 2010.p 222-239.
Singh B, Kapil R, Nandi M, Ahuja N. Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. Expert Opin Drug Deliv. 2011;8(10):1341–1360. Doi:10.1517/17425247.2011.605120
Sharma D, Maheshwari D, Philip G, Rana R, Bhatia S et al. Formulation and Optimization of Polymeric Nanoparticles for Intranasal Delivery of Lorazepam Using Box-Behnken Design: In-vitro and In Vivo Evaluation. BioMed Research International. 2014; 1-14 . Doi: 10.1155/2014/156010
Fedele L, Colla L, Bobbo S, Agresti F. Experimental stability analysis of different water-based nanofluids. Nanoscale Research Letters. 2011; 6(300):1-8 . Doi: 10.1186/1556-276X-6-300
Khatamifar M. et al. Preparation of Deferasirox in nano-scale by ultrasonic irradiation and optimization the amount and reaction time parameters. Int J Nano Dimens. 2015; 6 (4): 363-369.
Tadwee I, Shahi SR, Thube MW, et al. Spray dried nasal mucoadhesive microspheres of carbamazepine: preparation and in-vitro/ex-vivo evaluation. Int J Sci Publ Res Pharm. 2011; 2(1): 23–32.
Jain N, Gulat N, Kumar D, Nagaich U. Microspheres: Mucoadhesion based controlled drug delivery system. RGUHS J Pharm Sci. 2012; 2(3): 28-40.
Mahajan HS, Gattani SG. Nasal administration of ondansetron using a novel microspheres delivery system Part II: ex vivo and in vivo. Pharm Dev Technol. 2010;15(6): 653–657. Doi:10.3109/10837450903479970
Khan R, Prajapati SK, Singh G. Formulation and evaluation of mucoadhesive microspheres of flurbiprofen. Pharmacol Online. 2010;3: 659–70.
Taghavi F. Gholizadeh M, Saljooghi A. Deferasirox loaded on fumed silica nanoparticles used in cancer treatment. New J Chem. 2016; 40: 2696-2703. Doi:10.1039/C5NJ02790J
Cerchiara T, Luppi B, Chidichimo G, Bigucci F, Zecchi V. Chitosan and poly (methyl vinyl ether co maleic anhydride) microparticles as nasal sustained delivery system. Eur J Pharm Biopharm .2005; 61(3): 195–200. Doi:10.1016/j.ejpb.2005.05.005
Mushtaque M. Maria S, Dehghan MH, Zaheer Z, Khan S, Khan FA. Effects of solvents: Preparation and characterization of sustained release intranasal microspheres of rizatriptan benzoate. Journal of Innovations in Pharmaceutical and Biological Sciences. 2014;1: 68-71
Hassan F, Mohammed G, El-Hiti G, Alshanon A, Yousif E. Cytotoxic effects of tamoxifen in breast cancer cells. J Unexplored Med Data 2018;3:3. Doi:10.20517/2572-8180.2017.25
Thulasi G, Anusha D, Chellathai D. A Comparative Study on Viability of Mcf-7 Human Breast Cancer Cell Lines Using Piperine and Tamoxifen – An In-vitro Study with A Novel Mishmash. Biomed Pharmacol J. 2018;11(4): 1955-1959. Doi:10.13005/bpj/1568
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Nilima Thombre, Payal Jangam, Rinku Umarani , Neha Kulkarni; Sanjay Kshirsagar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
